Brief: Achilles Therapeutics Reports Q1 Loss Per Share Of $8.38
11/05/2021 13:59
May 11 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS REPORTS FIRST QUARTER 2021 FINANCIAL
RESULTS AND RECENT BUSINESS HIGHLIGHTS
* Q1 LOSS PER SHARE $8.38
* EXPECTS EXISTING CASH AND CASH EQUIVALENTS PLUS IPO
PROCEEDS ARE
SUFFICIENT TO FUND PLANNED OPERATIONS INTO H2 2023
Source text for Eikon: ID:nGNX9dJZtj
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement